NYSE:NAVB

Delisted

Navidea Biopharmaceuticals Stock News

Healthcare > Biotechnology

Buy NAVB

*Your capital is at risk

$0.0001

+0 (+0%)

At Close: Dec 30, 2025

Navidea Biopharma Reports $3M Private Placement

12:00am, Friday, 22'nd Mar 2019

Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

12:00am, Thursday, 07'th Mar 2019

Patterson Companies Sees FY19 Adj. EPS $1.40-$1.45

12:00am, Thursday, 28'th Feb 2019

Navidea Biopharma Reports Extension Of NYSE American Listing Until Mar. 31, 2019 To Regain Compliance

12:00am, Friday, 01'st Feb 2019

Navidea Biopharma Announces the Ohio Supreme Court has Dismissed a Petition Filed by Capital Royalty Partners

12:00am, Thursday, 24'th Jan 2019

Navidea Biopharma Reports Patent Extension For Lymphoseek For Added 5 Yers To May 12, 2025

12:00am, Friday, 07'th Dec 2018

Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty ...

12:00am, Thursday, 15'th Nov 2018

Navidea Biopharmaceutical Q3 EPS $(0.02) Down From $(0.01) YoY, Sales $231.458K Up From $223.669K YoY

12:00am, Wednesday, 07'th Nov 2018

Navidea Biopharma Shares Resume Trade, Now Up 4%

12:00am, Friday, 02'nd Nov 2018

Navidea Biopharmaceuticals Reportes Court Dismisses Claims Against Co. By Platinum-Montaur Life Sciences

12:00am, Wednesday, 31'st Oct 2018

Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American, Common Stock Will Continue To Be Listed

12:00am, Tuesday, 30'th Oct 2018

60 Biggest Movers From Yesterday

12:00am, Wednesday, 19'th Sep 2018

22 Stocks Moving In Tuesday's Pre-Market Session

12:00am, Tuesday, 18'th Sep 2018

Navidea Biopharmaceuticals shares are up 16.3% after the company reported acceptance into the National Institutes of Health Commercialization Accelerator Program.

Navidea Biopharmaceuticals Stock News

Navidea Biopharma Reports $3M Private Placement

Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Patterson Companies Sees FY19 Adj. EPS $1.40-$1.45

Navidea Biopharma Reports Extension Of NYSE American Listing Until Mar. 31, 2019 To Regain Compliance

Navidea Biopharma Announces the Ohio Supreme Court has Dismissed a Petition Filed by Capital Royalty Partners

Navidea Biopharma Reports Patent Extension For Lymphoseek For Added 5 Yers To May 12, 2025

Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty ...

Navidea Biopharmaceutical Q3 EPS $(0.02) Down From $(0.01) YoY, Sales $231.458K Up From $223.669K YoY

Navidea Biopharma Shares Resume Trade, Now Up 4%

Navidea Biopharmaceuticals Reportes Court Dismisses Claims Against Co. By Platinum-Montaur Life Sciences

Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American, Common Stock Will Continue To Be Listed

60 Biggest Movers From Yesterday

22 Stocks Moving In Tuesday's Pre-Market Session

Navidea Biopharmaceuticals shares are up 16.3% after the company reported acceptance into the National Institutes of Health Commercialization Accelerator Program.

Stocks Which Set New 52-Week Low Yesterday, August 16th

Top Fintech Company